Global Markets for Asthma and COPD Drugs

BCC Research
August 1, 2012
159 Pages - SKU: WA4866143
Countries covered: Global

The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.

Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%.

The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%.

COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.


Additional Information

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study is intended to provide readers with an understanding of the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. The study outlines the industry structure, competitive aspects, current developments, and future trends in the market, to assist in identifying areas of commercial interest and potential in the asthma and COPD indications.

The objectives of the study include the assessment of current market status, the analysis of marketed drugs, market revenues, company shares, unmet market needs, market challenges, and future trends. Future market revenues are forecast for the global market, major drug classes, individual disease indication, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of asthma and COPD.

REASONS FOR DOING THE STUDY

Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally.

The market for asthma and COPD drugs had global revenues in 2010 that exceeded $34 billion annually. These drugs enjoy tremendous commercial success, as illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. However, there is a perceived high level of unmet need in this market in terms of treatment options for asthma and COPD patients.

With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.

More Respiratory/Pulmonary reports by BCC Research

Pharmaceuticals: Pulmonary Drug Delivery Systems: Technologies and Global Markets by BCC Research
Pharmaceuticals: Pulmonary Drug Delivery Systems: Technologies and Global Markets REPORT HIGHLIGHTS The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 ...
Pulmonary Drug Delivery Systems: Technologies and Global Markets by BCC Research
The global pulmonary drug delivery technologies market which was $19.6 billion in 2010 is expected to be around $22.5 billion by 2011. This global market ...
Global Markets for Asthma and COPD Drugs by BCC Research
THIS REPORT: Provides an in-depth analysis of the global market for medications that treat asthma and chronic obstructive pulmonary disease Contains global market ...
See all reports like this >>

More Global Respiratory/Pulmonary reports

Idiopathic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014 by GlobalData
Idiopathic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, “Idiopathic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014 provides data on the ...
Global Non-small Cell Lung Cancer Market : 2014-2018 by TechNavio - Infiniti Research Ltd.
Global Non-small Cell Lung Cancer Market 2014-2018About Non-small Cell Lung CancerNon-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing ...
Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2014 by GlobalData
Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, “Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2014 provides data ...
Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014 by GlobalData
Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, “Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014 provides data ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 6,650  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!